About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Phase 3 Papulopustular Rosacea Study | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 3NCT01494467

Phase 3 Papulopustular Rosacea Study

The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosace...

Lead sponsor: Galderma R&D•40 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Galderma R&D

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. The subject has papulopustular rosacea with an Investigator Global Assessment (IGA) score rated 3 (moderate) or 4 (severe),
•2. The subject has at least 15 but not more than 70 inflammatory lesions (papules and pustules) on the face.

Exclusion Criteria

•1. The subject has particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin) or other facial dermatoses that may be confounded with papulopustular rosacea, such as peri oral dermatitis, facial keratosis pilaris, seborrheic dermatitis, and acne,
•2. The subject has rosacea with more than two nodules on the face.

Related studies

COMPLETEDPhase 1

Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties

NCT05675501 · Papulopustular Rosacea

COMPLETEDPhase 4

Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea

NCT01872715 · Papulopustular Rosacea

COMPLETEDPhase 3

A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea

NCT03276936 · Papulopustular Rosacea

COMPLETEDPhase 3

A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

NCT04608500 · Facial Papulopustular Rosacea

COMPLETEDPhase 3

A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea

NCT02393937 · Papulopustular Rosacea, Erythematotelangiectatic Rosacea

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 18, 2021Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment688

Start dateDec 2011

Last updatedFeb 18, 2021

Condition

Papulopustular Rosacea

Locations shown

Total Skin and Beauty

Birmingham, Alabama

Coastal Clinical Research, Inc.

Mobile, Alabama

Burke Pharmaceutical Research

Hot Springs, Arkansas

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 18, 2021Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions